(Q40165996)

18 September 2017

title

Survival improvement in thoracic cancer: progress from the last decade and beyond (English)

1 reference

18 September 2017

1 reference

Christian Manegold

1

1 reference

18 September 2017

Nicholas Thatcher

series ordinal

2

1 reference

18 September 2017

publication date

1 August 2007

1 reference

18 September 2017

1 reference

18 September 2017

volume

57 Suppl 2

1 reference

18 September 2017

page(s)

S3-5

1 reference

Global cancer statistics, 2002

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970420-8

7 January 2021

The changing epidemiology of lung cancer in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970420-8

7 January 2021

Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970420-8

7 January 2021

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970420-8

7 January 2021

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970420-8

7 January 2021

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970420-8

7 January 2021

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970420-8

7 January 2021

10.1016/S0169-5002(07)70420-8

Identifiers

DOI

1 reference

18 September 2017

1 reference